Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison.

This controlled comparison study evaluated objective and subjective cognitive function and their relationships with patient-reported symptoms (depression, fatigue, insomnia) in patients receiving tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and non-cancer controls. Patients with CML in chronic phase treated with the same oral TKI for ≥6 months ( = 90) and non-cancer controls ( = 87) completed a neurocognitive battery and self-report measures. Patients demonstrated worse overall neuropsychological performance  = .05) and verbal memory ( = .02) compared to controls. Patients were not more likely to meet criteria for impaired cognitive performance compared to controls (>.26). Patients reported worse subjective global and domain-specific cognitive complaints and less satisfaction with cognitive function compared to controls (s < .05). Patients also reported greater fatigue and insomnia symptoms (s < .001). In both groups, greater fatigue, insomnia, and depressive symptoms were associated with worse subjective cognition (s < .01). Longitudinal studies are needed to examine changes in cognitive function in patients before and during TKI treatment.